Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Uber Makes Morningstar List of Undervalued Growth Stocks

Growth stocks have surged 33% so far this year, and some have more room for gains, according to Morningstar.

The Street

10 Stocks Will Make You 30% Richer Than Others In A Year: Analysts

Analysts have the typical hopes for the S&P 500 in the next 12 months. But they're especially bullish on a small handful of stocks.

Investors Business Daily

Moderna signs deal to make mRNA vaccines for Chinese market

Moderna Inc. will push toward producing messenger RNA vaccines for China, seeking a foothold in the world’s second-largest pharmaceutical market even as geopolitical tensions rise.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

A Long-Awaited Vaccine For Lyme Disease is Tantalizingly Close — Here's When It Could Be Available

Over the past twenty years, Lyme disease cases have continued to climb, and we are finally tantalizingly close to another vaccine.

Inverse

UK regulator sued for not investigating Covid vaccine ‘misinformation’

Case brought against General Medical Council for failure to look into claimed links to heart problems and deaths

The Guardian - UK

Health care providers are adding cloud tech, but need to dream bigger

Currently, the application of cloud in the health care space is choppy.

Fortune

Cancer vaccines are already a reality. Here's what you need to know about the cutting-edge technology that could usher in an era of personalized medicine

The concept may seem torn from the plot of some futuristic sci-fi movie, or from the pages of some decades-old utopian novel far ahead of its time. But such wonders of science exist today.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Moderna Stock Rises After FDA Application For Updated Vaccine

Moderna's potential beyond COVID-19 is underappreciated, says analyst Eliana Merle, who upgraded the stock to Buy

Zenger

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In?

Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the current uncertain economic climate. Keep reading to find out.

StockNews.com

mRNA Vaccines Could Revolutionize Cancer Treatment

Here’s a look at the status of mRNA technology's application in cancer and when it might reach patients.

Inverse

Devastating virus few parents know about hits three babies a day

World-first vaccine trials have now begun in a bid to protect children from CMV

Wales Online

Growth Stocks Are Back — Analysts Like These 8 The Best

Growth stocks in the S&P 500 are racing back. And analysts are scrambling to choose their favorites.

Investors Business Daily

Scottish Mortgage sees share price fall by a third

Net asset value also fell by more than 17% during a year that has been 'painful for shareholders'

Insider UK

These Next-Generation Vaccines Could Upend Cancer Treatment As We Know It

New high-tech vaccines could help combat common yet deadly conditions like cancer and heart disease.

Inverse

Get all your
news in one place.

100’s of premium titles.
One news app.

The Walrus

The Vaccine Problem

To better weather future pandemics, the way countries procure vaccines needs to change radically

The New Daily

mRNA technology beat COVID-19, can it do the same for pancreatic cancer?

Half the pancreatic cancer patients in a new clinical trial were alive and cancer free after 18 months. Most usually die within three months.

The Hindu

FDA approves first vaccine for respiratory syncytial virus

The FDA has approved the first vaccine for respiratory syncytial virus (RSV).

Kiplinger

Moderna Stock Pops on Surprise Earnings Beat

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Moderna Jumps On Unexpected First-Quarter Profit Amid Plummeting Covid Sales

Moderna stock jumped Thursday on an unexpected first-quarter gain even as sales plummeted amid waning demand for Covid vaccines.

AFP

US becomes first country to approve RSV vaccine

Washington (AFP) - The United States on Wednesday approved the world's first vaccine for the Respiratory Syncytial Virus (RSV), the culmination of a decades-long hunt to protect vulnerable people from the common illness.

AFP

US issues world's first approval of RSV vaccine

Washington (AFP) - The United States on Wednesday approved the world's first vaccine for the Respiratory Syncytial Virus (RSV), the culmination of a decades long hunt to protect vulnerable people from the common illness.

Investors Business Daily

GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line

GSK stock jumped Wednesday after the drugmaker won the first-ever approval for an RSV vaccine, leading rivals Pfizer and Moderna.

The Texas Tribune

Attorney General Ken Paxton to investigate COVID-19 vaccine makers

Long an opponent of vaccine and mask mandates, the Republican said pharmaceutical companies may have misrepresented data. Pfizer strongly disagrees.

The Week

Lyme disease: vaccine could halt rise of tick-borne disease

A vaccine for Lyme disease could be available soon, according to reports.

Fortune

Moderna's CEO shares what it was like to leap from pre-revenue startup to Fortune 500 company

The COVID-19 vaccine turned Moderna into a household name. What's next for the company?

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Warner Bros Discovery

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.